Development and validation of a nomogram for predicting the early death of anaplastic thyroid cancer: a SEER population-based study

Cui, Hanxiao; Wang, Ru; Zhao, Xuyan; Wang, Shuhui; Shi, Xianbiao; Sang, Jianfeng

doi:10.1007/s00432-023-05302-z

Cited by 5 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study identified specific risk factors for all-cause early death and cancer-specific early death, such as gender, tumor size, M-stage, surgery, radiation, and chemotherapy. Early intervention and rescue can be applied to patients based on these risk factors to increase their possibility of survival ( 59 ).…”

Section: Discussionmentioning

confidence: 99%

Knowledge mapping of anaplastic thyroid cancer treatments: a bibliometric analysis (2000-2023)

Liu,

Yan,

Yang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

ContextAnaplastic thyroid cancer (ATC) is a relatively rare and extensively malignant kind of thyroid carcinoma. The poor prognosis and high mortality rate of ATC can be attributed to its invasive features and undifferentiated phenotype. At present, there is a lack of efficacious therapeutic options. In light of the elevated fatality rate, it is vital to possess a comprehensive comprehension of the scientific terrain pertaining to ATC. To gather the perspectives of different researchers about the topic of ATC treatment, we did a bibliometric network analysis, which offers a comprehensive view of the scholarly literature.MethodologyA systematic search was conducted on the WoSCC database to identify publications pertaining to ATC treatment between the years 2000 and 2023. In this bibliometric investigation, the tools VOSviewers, CiteSpace, and the R package “bibliometrix” were employed to investigate the general attributes, developmental framework, and academic frontiers of the subject matter.Results1223 publications in total, written by 6937 scholars from 53 areas and 1402 institutions and published in 358 scholarly journals, were analyzed. There has been a gradual increase in the quantity of publications pertaining to ATC treatment. The United States and China emerged as the most prominent nations. The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Counseling Center are prominent research institutions in highly productive countries. The journal Thyroid holds a prominent position within its discipline, being widely recognized as both the most popular and highly co-cited publication. According to the available data, Maria Cabanillas has authored the highest number of published articles, while RC Smallridge has received the highest number of co-citations. It turned out that the prevailing keywords encompassed expression, therapy, apoptosis, survival, activation, proliferation, metastasis, and other related terms. Immunotherapy, targeted therapy, and prognostic factors are the emerging research hotspots and trends.ConclusionsThis paper presents a complete overview of research trends and advancements in the treatment of ATC using bibliometric analysis. The acquisition of information will offer vital insights for funding and potential creative strategies in researching the treatment of ATC, which indicates the research frontiers as well as prevalent directions in recent years.

show abstract

Section: Discussionmentioning

confidence: 99%

Knowledge mapping of anaplastic thyroid cancer treatments: a bibliometric analysis (2000-2023)

Liu,

Yan,

Yang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Recent research has advanced the development of nomograms, offering highly accurate prognostic information for thyroid cancer, surpassing traditional methods like the AJCC staging system (27)(28)(29).…”

Section: Discussionmentioning

confidence: 99%

Development of a predictive nomogram for intermediate-risk differentiated thyroid cancer patients after fixed 3.7GBq (100mCi) radioiodine remnant ablation

Lu,

Li,

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

ObjectivesThe objective of this study was to develop a predictive nomogram for intermediate-risk differentiated thyroid cancer (DTC) patients after fixed 3.7GBq (100mCi) radioiodine remnant ablation (RRA).MethodsData from 265 patients who underwent total thyroidectomy with central lymph node dissection (CND) and received RRA treatment at a single institution between January 2018 and March 2023 were analyzed. Patients with certain exclusion criteria were excluded. Univariate and multivariate logistic regression analyses were performed to identify risk factors for a non-excellent response (non-ER) to RRA. A nomogram was developed based on the risk factors, and its performance was validated using the Bootstrap method with 1,000 resamplings. A web-based dynamic calculator was developed for convenient application of the nomogram.ResultsThe study included 265 patients with intermediate-risk DTC. Significant differences were found between the ER group and the non-ER group in terms of CLNM>5, Hashimoto’s thyroiditis, sTg level, TgAb level (P < 0.05). CLNM>5 and sTg level were identified as independent risk factors for non-ER in multivariate analysis. The nomogram showed high accuracy, with an area under the curve (AUC) of 0.833 (95% CI = 0.770–0.895). The nomogram’s predicted probabilities aligned closely with actual clinical outcomes.ConclusionsThis study developed a predictive nomogram for intermediate-risk DTC patients after fixed 3.7GBq (100mCi) RRA. The nomogram incorporates CLNM>5 and sTg levels as risk factors for a non-ER response to RRA. The nomogram and web-based calculator can assist in treatment decision-making and improve the precision of prognosis information. Further research and validation are needed.

show abstract

“…The initial outcomes of deep learning and artificial intelligence in the fields of diagnosis, image evaluation, treatment and outcome prediction have exhibited great potential. To ensure optimal results, it is crucial to adopt a multidisciplinary approach and formulate an individualized therapeutic regimen based on the principles outlined in surveillance, epidemiology, and end results[ 2 , 7 - 10 ].…”

Section: Advancements In Diagnosis Treatment and Management Strategie...mentioning

confidence: 99%

An overview of the contemporary diagnosis and management approaches for anaplastic thyroid carcinoma

Zhou,

Luo

2024

World J Clin Oncol

View full text Add to dashboard Cite

Thyroid carcinoma is a complex disease with several types, the most common being well-differentiated and undifferentiated. The latter, “undifferentiated carcinoma”, also known as anaplastic thyroid carcinoma (ATC), is a highly aggressive malignant tumor accounting for less than 0.2% of all thyroid carcinomas and carries a poor prognosis with a median survival of 5 months. BRAF gene mutations are the most common molecular factor associated with this type of thyroid carcinoma. Recent advances in targeted biological agents, immunotherapy, stem cell therapy, nanotechnology, the dabrafenib/trametinib combination therapy, immune checkpoint inhibitors (ICI) and artificial intelligence offer novel treatment options. The combination therapy of dabrafenib and trametinib is the current standard treatment for patients with BRAF-V600E gene mutations. Besides, the dabrafenib/trametinib combination therapy, ICI, used alone or in combination with targeted therapies have raised some hopes for improving the prognosis of this deadly disease. Younger age, earlier tumor stage and radiotherapy are all prognostic factors for improved outcomes. Ultimately, therapeutic regimens should be tailored to the individual patient based on surveillance and epidemiological data, and a multidisciplinary approach is essential.

show abstract

Development and validation of a nomogram for predicting the early death of anaplastic thyroid cancer: a SEER population-based study

Cited by 5 publications

References 34 publications

Knowledge mapping of anaplastic thyroid cancer treatments: a bibliometric analysis (2000-2023)

Knowledge mapping of anaplastic thyroid cancer treatments: a bibliometric analysis (2000-2023)

Development of a predictive nomogram for intermediate-risk differentiated thyroid cancer patients after fixed 3.7GBq (100mCi) radioiodine remnant ablation

An overview of the contemporary diagnosis and management approaches for anaplastic thyroid carcinoma

Contact Info

Product

Resources

About